Best-in-class mapping system for atrial fibrillation ablation procedures
The AcQMap™ is a breakthrough technology which integrates ultrasound and a proprietary mapping platform to provide a map of complex arrythmias with unprecedented accuracy and in real time to guide ablation therapy. The AcQMap™ received CE mark in May 2016.
CEO Vince Burgess
Advent Contact Shahzad Malik
Advent first invested in the Series A in 2011. Acutus most recently completed a $75m Series C financing in March 2016.
Publicly Listed
Acutus Medical Announces Pricing of Initial Public Offering
Press Release. August 6, 2020 CARLSBAD, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (NASDAQ: AFIB) today announced the pricing of its initial public offering of…
Read More
Acutus Medical’s New Contact Mapping Software Receives CE Mark
Press Release. FDA Clears Robust Second Generation AcQMap Platform CARLSBAD, Calif. and MANNHEIM, Germany, April 26, 2019 – Acutus Medical today announced CE mark approval for AcQMap contact mapping…
Read More
Acutus Medical® Receives FDA Clearance for Advanced Cardiac Mapping Technology for Complex Arrhythmias
Press Release. FDA clearance of the AcQMap® High Resolution Imaging and Mapping System and AcQMap® 3D Imaging and Mapping Catheter is a major milestone for Acutus Medical Clearance allows…
Read More
